Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Dr Reddy’s Laboratories ( (RDY) ).
Dr. Reddy’s Laboratories released its quarterly report for the period ending June 30, 2025, detailing its financial performance and operations. The report, reviewed by Ernst & Young Associates LLP, indicates no material modifications required for compliance with International Accounting Standards. This quarterly review highlights the company’s stable financial position and adherence to regulatory standards, which could positively impact its market reputation and stakeholder confidence.
The most recent analyst rating on (RDY) stock is a Buy with a $17.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The overall stock score for Dr Reddy’s Laboratories is solid, driven primarily by strong financial performance, indicating robust growth and stable operations. However, technical analysis suggests bearish momentum, and the valuation indicates limited dividend income potential, which slightly dampens the overall score.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a prominent pharmaceutical company based in Hyderabad, India. It specializes in the development and commercialization of a wide range of pharmaceutical products, including generic medicines, and operates in various international markets.
Average Trading Volume: 1,584,368
Technical Sentiment Signal: Strong Buy
Current Market Cap: $11.99B
For detailed information about RDY stock, go to TipRanks’ Stock Analysis page.